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Key Points
• Peptidic C3 inhibitors of the
compstatin family (Cp40)
efficiently prevent hemolysis
and opsonization of PNH
erythrocytes in vitro.
• Pharmacokinetic studies
show that sustained
therapeutic concentrations
can be achieved with both
Cp40 and its PEGylated
derivative, PEG-Cp40.
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated
intravascular hemolysis due to the lack of CD55 and CD59 on affected erythrocytes.
The anti-C5 antibody eculizumab has proven clinically effective, but uncontrolled C3
activation due to CD55 absence may result in opsonization of erythrocytes, possibly
leading to clinically meaningful extravascular hemolysis. We investigated the effect of
the peptidic C3 inhibitor, compstatin Cp40, and its long-acting form (polyethylene glycol
[PEG]-Cp40) on hemolysis and opsonization of PNH erythrocytes in an established in
vitro system. Both compounds demonstrated dose-dependent inhibition of hemolysis
with IC50 ∼4 mM and full inhibition at 6 mM. Protective levels of either Cp40 or PEG-Cp40
also efficiently prevented deposition of C3 fragments on PNH erythrocytes. We further
explored the potential of both inhibitors for systemic administration and performed
pharmacokinetic evaluation in nonhuman primates. A single intravenous injection of
PEG-Cp40 resulted in a prolonged elimination half-life of >5 days but may potentially
affect the plasma levels of C3. Despite faster elimination kinetics, saturating inhibitor
concentration could be reached with unmodified Cp40 through repetitive subcutaneous
administration. Inconclusion,peptide inhibitorsofC3activationeffectivelypreventhemolysisandC3opsonizationofPNHerythrocytes,
and are excellent, and potentially cost-effective, candidates for further clinical investigation. (Blood. 2014;123(13):2094-2101)
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a complex hema-
tologic disorder characterized by the expansion of hematopoietic
cells deﬁcient in glycophosphatidylinositol-anchored surface pro-
teins, including the complement regulators CD55 and CD59.1
Affected erythrocytes suffer from uncontrolled complement activa-
tion on their surface, and subsequent membrane attack complex
(MAC)-mediated intravascular hemolysis.2 The therapeutic anti-C5
antibody eculizumab (Soliris, Alexion) has proven effective in con-
trolling intravascular hemolysis in vivo, leading to remarkable
clinical beneﬁt in a majority of PNH patients.3,4 Yet, persistent C3
activation occurring during eculizumab treatment may lead to
progressive deposition of C3 fragments on affected erythrocytes and
subsequent C3-mediated extravascular hemolysis, possibly limiting
the hematologic beneﬁt of anti-C5 treatment.5,6 Thus, upstream
inhibition of the complement cascade seems an appropriate strategy
to improve the results of current complement-targeted treatment.7,8
Indeed, it has been recently documented that protein inhibitors of
the alternative pathway (AP) of complement activation, such as the
CD21/factorH (FH) fusion protein TT30 (Alexion) or the engineered
complement regulator mini-FH, efﬁciently prevent both hemolysis
and C3 deposition of PNH erythrocytes.9,10 Despite their high
efﬁcacy in vitro, the use of large proteins may potentially face chal-
lenges concerning pharmacokinetic properties and immunogenic-
ity. Smaller inhibitors based on the compstatin family of peptidic,
complement-targeted drugs may therefore offer an alternative option
for the treatment of PNH.
Compstatin was originally discovered as a 13-residue cyclic
peptide that selectively binds to human and nonhuman primate
(NHP) forms of the central complement component C3 and its active
fragment C3b.11 It thereby prevents the essential conversion of C3 to
C3b and impairs all initiation, ampliﬁcation, and terminal pathways
of complement.12 Given their ability to block complement activation
regardless of the initiation pathway, compstatin derivatives are
considered promising candidate drugs for treating different
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complement-mediated diseases.13One compstatin analog (originally
termed 4[1MeW]; see supplemental Figure 1 on the BloodWeb site
for an overview of relevant analogs) has demonstrated beneﬁcial results
in phase 1 clinical trials for the treatment of age-related macular
degeneration14 and is under clinical development by Potentia Phar-
maceuticals. The same analog is being developed by Apellis Phar-
maceuticals for other indications.13 Moreover, compstatin analogs
showed promising results in various disease models ranging from
hemodialysis to sepsis.12,15,16 In contrast to the local or time-
restricted administration of compstatin in the above-mentioned
clinical situations, therapeutic intervention in a chronic systemic
disease such as PNH imposes higher demands on drug properties,
particularly concerning pharmacokinetics. Over the past decade,
optimization studies have been conducted to develop compstatin
derivatives with improved characteristics for systemic use.17-19
The current lead analog Cp40 (clinically developed by Amyndas
Pharmaceuticals)13 shows strong binding afﬁnity for C3b (KD
;0.5 nM) and a plasma half-life (t1/2 ;12 hours) that exceeds
typical peptide drugs.18 Despite these favorable properties, it is
anticipated that a long-acting derivative of Cp40 based on site-
speciﬁc addition of polyethylene glycol (PEG) moieties may
beneﬁt a sustained pharmacologic complement inhibition as needed
in PNH.
By investigating the efﬁcacy of Cp40 and its long-acting
PEGylated derivatives regarding the protection of PNH erythrocytes
in vitro and evaluating their pharmacokinetic properties in NHP, we
describe a novel potential treatment option for PNH.
Methods
Human samples
Peripheral bloodwas collected from healthy volunteers (as a source for ABO-
matched normal sera) and patients suffering from purely hemolytic PNH. For
consistency, bloodwas serially drawn from the same 2 untreated patients who
exhibited a large PNH cell population (.10% on erythrocytes, .50% on
granulocytes) for all experiments. Additionally, serum was collected from
a PNH patient on eculizumab just after dosing; this was used for testing the
effect of anti-C5 on C3 fragment deposition in vitro. Blood was collected in
standard EDTA and serum Vacutainer tubes (BD Pharmingen, Milan, Italy)
after venipuncture according to standard procedures, following informed
consent as approved by the local Institutional Review Board. This study was
conducted in accordance with the Declaration of Helsinki.
Complement inhibitors
Cp40 (dTyr-Ile-[Cys-Val-Trp(Me)-Gln-Asp-Trp-Sar-His-Arg-Cys]-mIle-NH2;
1.7 kDa) was produced by solid-phase peptide synthesis as previously
described.18 Two forms of long-acting Cp40 were prepared: for N-terminal
PEGylation (PEG-Cp40), a Y-shaped PEGmoiety with an averagemolecular
weight of 40 kDa (Y-40K-NHS; JenKem Technology, Allen, TX) was added
to the N-terminal amine of Cp40 via a N-hydroxysuccinimide group. The
PEGylation reagent (120 mg/mL in acetonitrile/water 1:1) was mixed with
Cp40 (5 mg/mL) and N-methylmorpholine (12 mL/mL), and the reaction
mixture was rotated overnight at room temperature.20 Subsequently, the pH
was adjusted to 2 to quench the reaction. For C-terminal PEGylation (Ac-
Cp40-K-PEG), the N terminus of Cp40 was protected by acetylation and an
extra lysine residue was added at its C terminus during peptide synthesis; the
PEGylation reagent was coupled to the C-terminal lysine as described above.
A linear, sequence-scrambled compstatin derivative (Sar-Sar-Trp(Me)-Ala-
Ala-Asp-Ile-His-Val-Gln-Arg-mIle-Trp-Ala-NH2) was synthesized as an in-
active control. All peptides were puriﬁed by reversed-phase high-performance
liquid chromatography, characterized by mass spectrometry (MS), and tested
for the absence of endotoxin (,0.03 EU/mL).
Evaluation of complement inhibition activity and C3 binding
The ability of compstatin analogs to inhibit complement activation was
evaluated using an established enzyme-linked immunosorbent assay (ELISA)-
based method, based on the detection of C3b deposition after activation of
normal human serum (NHS) by immune complexes.17,18 Inhibitor concen-
trations of 0.01 mM to 10 mM were used.
The characterization of binding properties to C3 is described in supple-
mental “Methods.”
Assessment of PNH erythrocyte lysis and opsonization
Compstatin analogs were evaluated using an established in vitro system
assessing both intravascular hemolysis and C3 fragment deposition (as
a surrogate marker for C3-mediated extravascular hemolysis) on PNH
erythrocytes.9 Erythrocytes were obtained from peripheral blood after three
washings in saline, and subsequently incubated with Mg21-supplemented
sera from ABO-matched healthy individuals (NHS) at ﬁnal hematocrits of
2%; to reduce interexperiment variability, pooled sera from at least 3 subjects
(all with plasma C3 in the normal range) were used. AP activation was
achieved by acidiﬁcation using HCl (1:20 of HCl 0.1 N), which resulted in
a pH drop to a value between 6.7 and 6.9. Cp40, its PEGylated derivatives, or
an inactive control peptide were added to the tubes at different concentrations
before complement activation. After a 24-hour incubation at 37°C in acidiﬁed
NHS (AcNHS), hemolysis was quantiﬁed by ﬂow cytometry after staining
of the erythrocyte pellet with a ﬂuorescein isothiocyanate-conjugated
anti-C3 polyclonal antibody (Ab14396; Abcam, Cambridge, UK) and a
PE-conjugated anti-CD59 monoclonal antibody (59-PE; Valter Occhiena,
Torino, Italy), as previously described.9,21
The same anti-C3/anti-CD59 staining also served to assess opsonization
by evaluating the deposition of C3 fragments on erythrocytes exposed to AP
activation in the presence of C3 inhibitors using ﬂow cytometry at the end of
the hemolytic assay. The anti-C3 used in this study (Ab14396) has been
shown to bind both C3b and its degradation fragments, iC3b and C3dg.9
Injection of compstatin derivatives in NHPs
Pharmacokinetic evaluationwas performed at theAssociation forAssessment
and Accreditation of Laboratory Animal Care International-accredited
SICONBREC (Makati City, Philippines) in cynomolgus monkeys (Macaca
fascicularis). For PEG-Cp40, 2 healthy animals were sedated and injected
intravenously with 50 mg/kg of the compound (corresponding to ;2 mg/kg
of unmodiﬁed Cp40 when accounting for the .20-fold size difference)
dissolved in saline for injection. Blood samples (1 to 2 mL) were collected
immediately before and at various time points after compound injection (1 and
2 hours; 1, 2, 4, 7, 9, and 14 days) and mixed with EDTA to prevent
coagulation. In addition, Cp40 was administered via subcutaneous injection.
Initially, a single injection of 2mg/kgCp40was administered to 2 animals and
blood samples were collected before and after the injection (2, 5, and 30
minutes; 1, 2, 4, 6, and 24 hours). Based on the results of this single dose,
a regimen of repetitive subcutaneous injectionswas developed: Cp40 (1mg/kg)
was injected in 2 animals every 12 hours (4 doses in total) and blood was
collected at various time points (0.5, 4, 8, and 12 hours after each injection) as
described above; and aﬁnal blood collectionwas performed after 72 hours (ie,
36 hours after the last injection). Blood sampleswere centrifuged at;8003 g
for 10minutes to obtain plasma, and immediately frozen until further analysis.
All NHP studies were performed in accordance with animal welfare laws and
regulations, as approved and enforced by the SICONBREC IACUC.
Monitoring of plasma levels of inhibitors and C3
Total inhibitor levels (C3-bound and free) were determined by extracting
compstatin analogs from plasma samples using solid-phase extraction (SPE)
and quantifying them by reversed-phase liquid chromatography coupledwith
MS, essentially as described before and in supplemental “Methods.”18
The baseline plasma level of C3 before the start of each experiment was
determined using ELISA as previously described.18 In addition, western
blotting was performed to monitor C3 levels during the course of treatment.
Plasma samples at various time points of each treatment were diluted 10-fold
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in phosphate-buffered saline; 1mLof eachdiluted samplewas subjected to 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing
conditions and transferred to nitrocellulose membranes before detection with a
peroxidase-conjugated polyclonal goat antihuman C3 antibody (MP Biomed-
icals, Solon, OH). Plasma levels of transferrin, detected with a peroxidase-
conjugated polyclonal rabbit antihuman transferrin antibody (Acris, SanDiego,
CA), were analyzed as an internal control after stripping the anti-C3 antibody.
Results
Design and activity of Cp40 and its PEGylated derivatives
Although Cp40 exhibits favorable pharmacokinetic properties,18 we
aimed to further increase the plasma residence of the inhibitor by
adding a 40-kDa PEGmoiety as a means of reducing renal ﬁltration.
The crystal structure of compstatin with a C3 fragment revealed that
the terminal amino acids of this cyclic peptide are not essential for
binding and may be modiﬁed.22 Derivatives of Cp40 were therefore
prepared that contained PEG either directly linked to the N terminus
(PEG-Cp40) or to the C terminus after introducing a lysine residue
(Ac-Cp40-K-PEG) (Figure 1A). Characterization of the binding to
C3 showed that both PEGylated analogs featured slower association
rates, due to either an impact of the larger molecule on the diffusion
rate or lower accessibility to the binding site of surface-bound C3;
however, the complex stability (ie, dissociation rate constant) was
similar to unmodiﬁed Cp40 (supplemental Figure 2). As the primary
target for Cp40 is circulating C3, and PEGylated Cp40 derivatives
are expected to remain above saturating concentrations for an
extended time, the association rate is considered less important
for overall activity of the inhibitors. Indeed, a comparison of the
compstatin derivatives in a complement activation assay showed
that the inhibitory activity of PEG-Cp40 was highly comparable to
Cp40, with Ac-Cp40-K-PEG exhibiting a minor rise in IC50. Cp40
and its PEGylated forms were more potent than compstatin analog
4(1MeW), which features a lower degree of structural modiﬁcation
(Figure 1B and supplemental Figure 1).13,23
Effects of Cp40 and PEGylated derivatives on hemolysis and
opsonization of PNH erythrocytes
The activity of Cp40 and its long-acting derivatives for preventing
intravascular hemolysis was tested in an established in vitro model
using patient-derived erythrocytes.9,10 A total of 10 experiments
were performed on erythrocytes obtained from 2 untreated PNH
patients. Activation of the AP in the absence of inhibitors resulted in
almost complete hemolysis of PNH erythrocytes (97 6 3% after
24 hours).When added toNHS before acidiﬁcation, Cp40 resulted in
a concentration-dependent inhibition of hemolysis, with an IC50 of
;4mMand full inhibition at 6mM(Figure 2A).A control peptide did
not exert any effect on hemolysis (996 1%) even at concentrations
up to 30 mM. PEG-Cp40 resulted in a similar inhibitory potency
(IC50 ;4 mM; full inhibition ;6 mM), whereas Ac-Cp40-K-PEG
showed a reduced activity (IC50 ;7 mM; full inhibition ;10 mM;
Figure 2A). Thus, inhibition of AP-mediated complement activation
with compstatin analogs efﬁciently disabled MAC formation on
CD552/CD592 PNH erythrocytes. Due to the lower activity of Ac-
Cp40-K-PEG in the complement activation assay and the hemolysis
model, this derivative was not included in subsequent studies.
A major advantage targeting early complement activation (ie, at
the level of C3) in PNH is the possible effect on continuous
opsonization of PNH erythrocytes, which is thought to contribute
to extravascular lysis.1,8 We tested the antiopsonic activities of
Cp40 and PEG-Cp40 using the assay described above. Flow
cytometric analysis of PNH erythrocytes after incubation in
AcNHS conﬁrmed the disappearance of type III PNH eryth-
rocytes due to intravascular lysis in the absence of inhibitors
(Figure 2B). However, in the presence of inhibitory concen-
trations of Cp40 and PEG-Cp40, this population remained intact.
Importantly, no C3 fragment deposition was detectable on sur-
viving erythrocytes when using a polyclonal antibody that reacts
with opsonic C3 fragments (Figure 2B). This was in contrast to
observations with anti-C5 treatment in the same in vitro assay
(performed using serum from a patient just dosed with eculizumab;
Figure 2B),24 and in vivo,9 which preserved the type III population
but led to a marked increase in C3-derived opsonins on the surface of
these erythrocytes. These data conﬁrm that inhibition at the level of
C3 activation counterbalances the lack of both CD55 and CD59
on PNH erythrocytes, thereby fully disarming the harmful activity
of complement (Figure 2C).9
Figure 1. Preparation and characterization of compstatin Cp40 and long-acting
derivatives thereof. (A) Schematic representation of the PEGylation strategy: PEG-
Cp40 was prepared by adding a reactive two-arm branched PEG moiety of 40 kDa to
the unprotected amino terminus of Cp40. In the case of Ac-Cp40-K-PEG, the N
terminus was acetylated, a C-terminal lysine residue was added to the peptide during
synthesis, and the PEG reagent was reacted with the lysine side chain. The
dipeptide fragment used for the mass spectrometric quantification of PEG-Cp40 in
plasma is indicated in red. (B) Evaluation of the complement inhibitory activity of
Cp40 and its PEGylated derivatives using a complement activation ELISA. The
clinically developed analog 4(1MeW)14 is shown as a control (for more information on
individual compstatin analogs, see also supplemental Figure 1). The panel shows
a representative plot out of 3 separate experiments.
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Pharmacokinetic profile of PEG-Cp40 in NHPs
The effect of PEGylation on the plasma half-life of Cp40 was
assessed by pharmacokinetic proﬁling of PEG-Cp40 in NHP after
a single intravenous injection (Figure 3A). Blood samples spanning
a period of 2 weeks postinjection from 2 animals showed a repro-
ducible pharmacokinetic proﬁle with a slow terminal elimination
phase and a t1/2 value of 5.5 days (Figure 3B). Inhibitor concen-
trations appeared to be independent on the individual baseline level
of plasma C3 and, at the dosage used in this study, remained above
target level for at least 1 week (Figure 3B). No signs of adverse
effects were detected in either of the animals treatedwith PEG-Cp40.
As C3 undergoes a turnover in plasma (through mechanisms that
have not been fully elucidated),25-27 we investigated whether the
strong binding of a PEGylated inhibitor at saturating concentrations
may inﬂuence the plasma proﬁle of C3. Since the PEGmoiety caused
interference with antibody-based methods for C3 quantitation (eg,
ELISA; data not shown), western blot analysis was employed for
semiquantitative analysis of C3 levels during the course of the
experiment. Upon injection with PEG-Cp40, both animals showed
bands for the C3 a- and b-chain growing in intensity and reaching
peak levels between days 4 and 7 (Figure 3C), thereby suggesting
slow accumulation of plasmaC3 in the presence of PEG-Cp40.Hence,
PEGylation creates a long-acting form of Cp40 with .10-fold
increased plasma residence, but the administration of PEGylated
compstatin may potentially affect the plasma proﬁle of C3.
Subcutaneous injection of unmodified Cp40 as
a multidose regimen
Although PEG-Cp40 exhibited enhanced plasma residence, un-
modiﬁed Cp40 itself showed a beneﬁcial pharmacokinetic proﬁle
with a half-life of 12 hours.18 Therefore, we evaluated the potential
of subcutaneous injection of Cp40 as an alternative strategy for long-
term systemic administration. A single subcutaneous injection of
2 mg/kg Cp40 resulted in an immediate increase in plasma inhibitor
levels, with a peak at 4 hours and detectable Cp40 concentrations 24
hours postinjection (Figure 4A). In comparison with previous ex-
perimentswith single intravenous injections,18Cp40 reached a lower
peak concentration but remained in excess of the C3 level for an
extended period, likely due to continuous absorption from the sub-
cutaneous depot. This pharmacokinetic proﬁle suggested that
saturating inhibitor levels may be reached with repetitive injections
of Cp40 at the range of its half-life even at a lower dose. To verify
this hypothesis, we employed a dosing schedule of 4 consecutive
subcutaneous injections of 1 mg/kg at 12-hour intervals (Figure 4B).
Analysis of Cp40 levels in plasma showed that each injection raised
the inhibitor concentrationwithin 0.5 to 4 hours, followed by a steady
yet incomplete elimination (Figure 4C), hence closely resembling
the proﬁle of the single subcutaneous injection (Figure 4A). In
contrast to the intravenous injection of PEG-Cp40 (Figure 3B),
the plasma concentration of unmodiﬁed Cp40 in the subcuta-
neous regimen appeared to be inﬂuenced by the C3 level of the
Figure 2. Effect of C3 inhibitors on hemolysis and C3 fragment deposition of
PNH erythrocytes. (A) Dose-response curves from the in vitro hemolysis assay with
Cp40 (red) and its long-acting derivatives PEG-Cp40 (blue) and Ac-Cp40-K-PEG
(green). Lysis of PNH erythrocytes (y-axis) is expressed as a relative percentage of the
lysis observed without any inhibitor (in each experiment, 100% represents the lysis
observed in AcNHS) relative to the concentration of the C3 inhibitors (x-axis). Curves
represent the mean of 10 experiments performed on samples obtained from 2 PNH
patients; error bars represent standard deviations. (B) Flow cytometry assessment of
C3 fragment deposition on the surface of erythrocytes from untreated PNH patients.
Dot plots show intact erythrocytes as gated by physical parameters; CD59 (59-PE
monoclonal Ab; y-axis) vs C3 fluorescein isothiocyanate (Ab14396 polyclonal Ab;
x-axis). Scheme of erythrocyte populations and potential pattern of C3-fragment
deposition on normal, type II, and type III PNH erythrocytes as observed in the
fluorescence-activated cell sorter plots (top); unmanipulated fresh erythrocytes
(negative control) and erythrocytes incubated in the presence of eculizumab (acidified
ABO-matched serum from a patient on eculizumab, positive control for C3 deposition)
(middle, from left to right); and erythrocyte pellets after incubation in acidified ABO-
Figure 2 (continued) matched NHS in the absence of inhibitors (positive control for
hemolysis) and in the presence of blocking concentrations of Cp40 and PEG-Cp40.
Plots show representatives out of the 10 experiments (bottom, from left to right). (C)
Schematic representation of activity spectrum of Cp40 in comparison with anti-C5
therapy. Eculizumab only blocks MAC formation and thus intravascular lysis, thereby
enabling possible C3 opsonization of surviving erythrocytes and subsequent
extravascular hemolysis. C3 inhibitors such as Cp40 prevent C3 activation upstream,
thereby preventing both intravascular lysis and possible C3-mediated extravascular
lysis via CR.
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treated animal; importantly, saturating inhibitor concentrations
could be reached within 2 to 3 injection cycles for both animals
(Figure 4C). While a direct pharmacodynamic assessment of the
Cp40 treatment was limited by the absence of an in vivo PNHmodel,
and by the fact that plasma samples were collected in EDTA (which
impairs direct use in complement functional assays), the assumption
that antihemolytic activity can bemaintained throughout the treatment
period was supported by an in vitro model using plasma from one of
the animals used in the subcutaneous treatment study (supplemental
Figure 3). No adverse effects were observed in the animals, and no
increase of C3 levels was detected during this multidose treat-
ment (Figure 4D). Therefore, subcutaneous administration of Cp40
presents a valuable option for long-term systemic treatment of PNH
and other complement-related diseases.
Discussion
Although eculizumab has dramatically improved the treatment of
PNH,3,4,28 there are unmet clinical needs, as approximately one-third
of PNH patients insufﬁciently respond to the drug and remain
Figure 3. Pharmacokinetic evaluation of PEG-Cp40 in NHPs. (A) Dose scheme
for PEG-Cp40 administration: a single dose of 200 mg PEG-Cp40 was injected
intravenously into 2 cynomolgus monkeys at time 0 (green arrow) and blood samples
were drawn at various time points (red arrows). Given the size difference between
Cp40 (1.7 kDa) and PEG-Cp40 (;40 kDa), the selected dose corresponds to ;2 mg
of active peptide per kg. (B) Monitoring of PEG-Cp40 plasma concentrations
as determined by ultra performance liquid chromatography-high definition mass
spectrometry (after fragmentation using subtilisin-A and SPE). Baseline levels of
plasma C3 (measured by ELISA in T0 sample) are depicted as dotted lines for each
animal. Note that the 1 and 2 hour postinjection blood draws were not included in this
analysis. (C) Change of plasma C3 levels during the treatment with PEG-Cp40;
western blot analysis after 10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (reducing conditions) was performed with plasma samples collected at
different time points and a polyclonal C3 antibody was used for detection (top).
Although the antibody recognized both chains of C3, the reactivity with the a-chain
was generally higher. Plasma levels of an unrelated protein (transferrin) were used
as an internal control on the same membrane after stripping and reprobing with
a transferrin antibody (bottom). Panel shows a representative blot from at least
2 independent analyses of samples from 2 animals each.
Figure 4. Subcutaneous administration of Cp40 in NHPs. (A) Pharmacokinetic
profile of Cp40 in plasma samples collected 2, 5, and 30 minutes and 1, 2, 4, 6, and
24 hours after a single subcutaneous injection (2 mg/kg) in cynomolgus monkeys.
Baseline levels of plasma C3 (measured by ELISA) are depicted as dotted lines for
each animal. (B) Dose scheme for optimized Cp40 administration study: 4 doses of
Cp40 (1 mg/kg each) were injected subcutaneously into 2 cynomolgus monkeys at
a time interval of 12 hours (green arrows) and blood samples were collected 30
minutes, and 4, 8, and 12 hours after each injection, with an additional collection 72
hours after the start of the experiment (red arrows). (C) Monitoring of Cp40 plasma
concentrations as determined by ultra performance liquid chromatography-high
definition mass spectrometry (after SPE). Baseline levels of plasma C3 (measured
by ELISA in T0 sample) are depicted as dotted lines for each animal. The
dependence of the Cp40 concentration profiles on the baseline C3 level of each
animal is expected to be caused by target-dependent elimination kinetics, as
suggested in previous studies.18 (D) Plasma levels of C3 (top) and transferrin
(internal standard; bottom) during the treatment with Cp40 as determined by western
blot analysis (in analogy to Figure 3C). Panel shows a representative blot from at
least 2 independent analyses of samples from 2 animals each.
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dependent on transfusions.3,4 Diverse factors may be responsible for
the insufﬁcient response to anti-C5 therapy. Bone marrow failure is
the most obvious reason for a poor hematologic response, and this
condition may require additional or alternative speciﬁc etiologic
treatment (ie, either bone marrow transplantation or immunosup-
pression).29 “Breakthrough” intravascular hemolysis has been des-
cribed in about 10% to 15% of PNH patients,30 potentially requiring
increased dosages of eculizumab. Moreover, the deposition of C3
fragments on PNH erythrocytes has been observed in almost all PNH
patients on eculizumab.5,6,31-33 This opsonization of PNH eryth-
rocytes, and their subsequent recognition by complement receptors
(CR) on phagocytic cells, results in extravascular hemolysis that
is considered another, and likely the most important, cause for the
insufﬁcient response to eculizumab. Upstream complement inhibition
at the level of C3 or the C3 convertase has therefore been considered
a promising approach.8,13 Successful in vitro studies have been
conducted with an antibody against C3b (mAb 3E7),34 the fusion
protein TT30 that combines regulatory domains of FHwith the iC3b/
C3d-binding domains of CD21,9,35 and a novel engineered inhibitor
that links the regulatory and surface recognition areas of FH
(mini-FH).10 TT30 is currently being evaluated in a phase 1 clinical
trial enrolling PNH patients.36 Although these inhibitors prevent
both opsonization and hemolysis, their protein nature may un-
favorably affect clinical development.13 In this study, we identify
members of the compstatin family of C3 inhibitors as promising
candidates for the development of improved treatment strategies for
PNH.We demonstrate that Cp40 and its long-acting derivative PEG-
Cp40 prevent both intravascular hemolysis and opsonization in
vitro, while featuring distinct pharmacokinetic proﬁles that provide
alternatives for tailoring treatment regimens. This proof-of-efﬁcacy
for upstream complement inhibition using small-size inhibitors
marks an important step toward the development of comprehensive
and cost-effective novel complement-targeted treatments.
Complement inhibition at the level of C3 faces speciﬁc chal-
lenges, since high plasma levels (;0.7 to 1.5 mg/mL) and rapid
turnover of this central component27 requires comparatively large
inhibitor doses for achieving sustained target saturation in a
stoichiometric fashion.13,27 In comparison with protein-based C3
inhibitors, Cp40 offers advantages concerning drug burden due to
its small size (1.7 kDa); moreover, given its high plasma stability
and its tight binding to circulating C3, Cp40 features a pharmaco-
kinetic proﬁle that is more favorable than that typically seen with
peptidic drugs.18,37 Our study now indicates the clinical potential
of Cp40, even in its nonmodiﬁed form, in diseases that require
systemic long-term treatment. Due to the high bioavailability and
sustained plasma proﬁle after subcutaneous administration inNHP,
therapeutic concentrations sufﬁcient for sustained complement
inhibition (supplemental Figure 3) could be achieved after repet-
itive injections at a comparatively low dose of 1 mg/kg. This
anticipates a regimen of twice-daily (or even daily) injection,
potentially allowing for patient self-administration as it is currently
evaluated for other complement-targeted drugs.36,38 A subcutane-
ous regimen based on our preclinical data would translate to a daily
dose of 140 mg of unmodiﬁed Cp40 for a 70 kg patient. Given the
recent improvements in peptide production, the cost of which
can drop below $1 per amino acid per gram during scale-up,37
compstatin may likely be more cost-effective in comparison with
current eculizumab treatment or other protein-based complement
inhibition.
Despite these advantages, long-term inhibition of plasma C3
may beneﬁt from measures that prolong the half-life of Cp40 in a
target-independent manner, and lead us to investigate PEGylation
strategies that are commonly applied to therapeutic proteins and
peptides.39-41 PEGylation at the N terminus of Cp40 appears
particularly attractive, as it can be performed without intermediate
steps (such as acetylation and the addition of lysine residues
required for Ac-Cp40-K-PEG) and minimally affects the inhib-
itory efﬁcacy. With a .10-fold increase in plasma residence, the
addition of a 40-kDa PEG group improved the pharmacokinetic
properties to a range that is closer to eculizumab and other
therapeutic antibodies,42,43 possibly allowing dosage intervals of
1 to 2 weeks. This enhancement of half-life can be attributed to
reduced glomerular ﬁltration of the large PEGylated compound,
primarily in the free circulating form, when compared with the
;20-fold smaller parent peptide. In agreement with this hypoth-
esis, and in contrast to unmodiﬁed Cp40, the plasma concentrations
of PEG-Cp40 were largely independent of the baseline C3 level of
the treated animal, thereby suggesting a slow, target-independent
initial elimination. While no adverse reactions to PEG-Cp40 were
observed in the treated animals during the time frame of the
pharmacokinetic study, the detected accumulation of plasma C3
was unanticipated. The metabolic turnover of C3 is described to be
more rapid and complex compared with other plasma proteins, and
may involve clearance via activation (through the so-called tick-
over mechanism), degradation, and uptake of fragments through
cellular CR.27 Our data suggest that PEG-Cp40 may result in
a reduced turnover of C3 that circulates in a stable complex with
this 40-kDa inhibitor, whereas at least within the 3-day treatment
period, no comparable accumulation of C3 was observed after
injection of unmodiﬁed Cp40. Although the consequences of this
accumulation may be marginal in vivo if the inhibitor stays in
excess of C3, the impact of this ﬁnding on therapeutic efﬁcacy, the
potential need of dose escalation, and possible rebound effects
warrants further investigation. Furthermore, although generally
considered safe, PEGylationmay change the immunogenicity and
safety proﬁles of peptide/protein drugs, and cases of anti-PEG
antibodies or vacuolation have been described.39,40 Finally,
PEGylation causes a profound increase in production cost com-
pared with the parent peptide, which, however, may be at least
partially offset by reduced dosage intervals. 44
Whereas PNH is primarily driven by AP activation, many
aspects concerning initiation and exacerbation of the erythrocyte-
directed complement attack are not yet elucidated; contributions
of the classical and/or lectin pathways cannot be excluded,
especially at times of infection and subsequent hemolytic crises.
Indeed, clinical observations suggest that massive complement
activation during infections may overpower terminal complement
inhibition as delivered by eculizumab (A.M.R. and R.N., personal
communication),30 resulting in intravascular hemolysis due to
“pharmacodynamic breakthrough” that likely results from an ex-
cess in C3 andC5convertase,whichmaycleave freeC5 that becomes
transiently available from the C5:anti-C5 complex. Given that it
is unclear which complement pathway is dominant during these
paroxysms, compstatin analogs would offer an advantage not only
over C5-targeted inhibition but also over pathway-speciﬁc C3
convertase inhibitors and ensure maximum efﬁcacy for preventing
hemolysis in all circumstances. On the other hand, concerns have
been raised about chronic impairment of C3 activation, particularly
regarding increased susceptibility for infections and immune-
complex–mediated diseases. Although such conditions have been
described for subjects with inherited C3 deﬁciency, there is no
consistent clinical phenotype.13,45,46 Moreover, previous studies
reported that low residual levels of C3 are sufﬁcient for microbial
defense,47,48 and even complete C3 inhibition leaves some opsonic
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functions intact (eg, via C4b and pattern recognition molecules
of the classical/lectin pathway). To date, preclinical and clinical
evaluation of complement inhibitors have resulted in favorable
safety proﬁles.13 Severe infection has not emerged as a frequent
complication in PNH patients receiving eculizumab,30 though
Neisseria meningiditis infection remains a rare but potentially
life-threatening event requiring a speciﬁc vaccination program.
Consistently, anti-meningococcal vaccination was also invoked
in the clinical trials of theAP-speciﬁc inhibitor TT30,36 andwill have
to be considered (possibly combined with prophylactic anti-
microbial therapy) in future clinical trials with compstatin analogs
or other C3 inhibitors. In this safety perspective, given that the in
vivoeffects of long-termbroadC3 inhibition are not known, repetitive
subcutaneous injections of unmodiﬁed Cp40 should be favored
over PEG-Cp40, since the drug could be phased out more efﬁciently,
if needed. It will be only through extended clinical investigations
that potential risks and clinical beneﬁts entailed by each strategy of
complement-targeted modulation in PNH can be established to select
ideal candidate agents for clinical development. Due to their com-
paratively small size and peptidic nature, compstatin analogs have
the advantage of substantially lower production costs,37 making them
very appealing when seeking an affordable treatment option that is
accessible to the majority of PNH patients worldwide.
In conclusion, we demonstrate that two members of the
compstatin family (ie, Cp40 and its PEGylated derivative), efﬁciently
prevent C3 activation and opsonization on PNH erythrocytes in
vitro, which predicts the inhibition of both MAC-mediated intra-
vascular and C3-mediated extravascular hemolysis in vivo.
PEGylation of compstatin appears to be an intriguing strategy
to reach long-term C3 inhibition in systemic complement-related
diseases due to its enhanced plasma residence and high efﬁcacy,
but additional studies will be needed to evaluate its effects on
plasma C3 proﬁles and suitable dose regimens. Meanwhile,
subcutaneous injection of Cp40 offers an attractive alternative for
immediate translational plans of systemic administration with
distinct therapeutic advantages. Thus, this family of peptidic C3
inhibitors represents a novel class of complement therapeutics
that is moving forward to clinical translation in PNH and other
complement-mediated diseases.
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